Adam Peyton, DO

Adjunct Assistant Professor of Medicine in Surgery
Department: Surgery
Contact information
University of Medicine and Dentistry of NJ
Newark, NJ
Newark, NJ
Education:
BA (Biology)
Rutgers University, 1998.
DO (Doctor of Osteopathy)
Philadelphia College of Osteopathic Medicine, 2002.
Permanent linkBA (Biology)
Rutgers University, 1998.
DO (Doctor of Osteopathy)
Philadelphia College of Osteopathic Medicine, 2002.
Selected Publications
Ho SB, Monto A, Peyton A, Kaplan DE, Byrne S, Moon S, Copans A, Rossaro L, Roy A, Le H, Dvory-Sobol H, Zhu Y, Brainard DM, Guyer W, Shaikh O, Fuchs M, Morgan TR; VALOR study team: Efficacy of Sofosbuvir plus Ribavirin in veterans with hepatitis C virus genotype 2 infection, compensated cirrhosis, and multiple comorbidities. Clinical Gastroenterology & Hepatology 15(2): 282-288, Feb. 2017 Notes: (Epub May 27, 2016).Essrani R, Hickey P, Peyton A, Shah H: Denture misadventure: The tooth about your colon. American Journal of Gastroenterology 112(Suppl 1): S1532, 2017.
Sclair SN, Hernandez MD, Vance E, Gilinski D, Youtseff H, Toro M, Antoine M, Jeffers LJ, Peyton A: Sofosbuvir and Simeprevir combination therapy for HCV genotype 1 infection: Results of a single-center VA experience. Gastroenterology & Hepatology (NY) 12(8): 490-497, Aug. 2016.
Ho SB, Monto A, Peyton A, Kaplan DE, Byrne S, Moon S, Le H, Copans A, Rossaro L, Zhu Y, Brainard D, Guyer W, Shaikh O, Fuchs M, Morgan TR: Sofosbuvir plus ribavirin for 12 weeks in genotype 2 HCV compensated cirrhotic patients: A comparative analysis of VALOR-HCV SVR data to registration trials and real world cohorts. Gastroenterology 150(4 Suppl 1): S925, 2016.
Ho S, Monto A, Peyton A, Kaplan DE, Moon B, Zhu Y, Seyedkazemi S, Rossaro L, Brainard DM, Guyer W, Shaikh OS, Fuchs M, Morgan TR: Twelve weeks of Sofosbuvir plus Ribavirin is effective for treatment of genotype 2 HCV in difficult to treat US veterans with cirrhosis: Results of the VALOR-HCV Study. American Association for Study of Liver Diseases, San Francisco, CA Dec. 2015 Notes: Oral presentation.
Gutierrez JA, Carrion A, Bhamidimarri KR, Peyton AL: Reply. Liver Transplantation 21(10): 1330, Oct. 2015.
Bhamidimarri K, Czul F, Peyton A, Levy C, Hernandez M, Jeffers L, Roth D, Schiff E, O’Brien C, Martin P : Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. Journal of Hepatology 63(3): 763-765, Sept. 2015 Notes: (Epub June 18, 2015) (Erratum in: J Hepatol 2015 Dec; 63[6]:1542).
Gutierrez J, Carrion A, Avalos D, O’Brien C, Martin P, Bhamidimarri K, Peyton A: Sofosbuvir and Simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transplantation 21(6): 823-830, June 2015.
Avalos D, Schweitzer M, Peyton A, Bhamidimarri K, Gutierrez J : Insurance approval patterns for IFN-free regimens in HCV: Impact of national guidelines. Digestive Disease Week, Washington, DC May 2015 Notes: Oral presentation.
Sclair S, Peyton A, Youtseff H, Vance E, Hernandez M, Jeffers L: Comparative cost-effectiveness of Sofosbuvir regimens for treatment of HCV genotype 1 at a single VA hepatology practice. Digestive Disease Week, Washington, DC May 2015 Notes: Oral presentation.